Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Financial aspects of targeted therapy of lung cancer as compared to conventional chemotherapy].

Magyar onkologia - 1 Jan 2007

Moldvay Judit

Abstract excerpt

Lung cancer is the leading cause of cancer death worldwide, and it is responsible for 20-25% of all cancer deaths. In Hungary, more than 4,000 lung cancer patients receive chemotherapy every year, and of them 3,000 suffer from non-small cell lung cancer. Despite the rapid development in antitumor treatment options, the response rates of chemotherapies in non-small cell lung cancer still remain between 15-35%....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Drug Costs
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hungary

Share to Patient Selection

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to ras Proteins

Source

Identifiers

PMID: 17922058

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

[Financial aspects of targeted therapy of lung cancer as compared to conventional chemotherapy].PMID 17922058Read ↗

[Molecule pathology in the treatment of lung cancer-Interdisciplinary view of the importance in thoracic surgery].Semantic proximity Read ↗

[Pharmacoeconomic analysis of gefitinib therapy in patients with non-cell cell lung cancer].Semantic proximity Read ↗

[Targeted therapies in the treatment of non-small cell lung cancer].Semantic proximity Read ↗

Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review.Semantic proximity Read ↗

[Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].Semantic proximity Read ↗

High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group).Semantic proximity Read ↗

Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.Semantic proximity Read ↗

Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany.Semantic proximity Read ↗

Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study.Semantic proximity Read ↗

[Results of questionnaire on decision-making to treat advanced non-small cell lung cancer based on American and European practical guidelines].Semantic proximity Read ↗

Could molecular pathology testing in lung cancer be more cost-effective?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.